When it doesn't hit $20 next Friday, you can just keep moving the date. Eventually you'll be right.
Thought I saw you on the ACAD board not long ago saying you shorted the stock?
I'm still waiting on your newsletter. Your 100% correct track record is phenomenal.
Not saying the bears are right, just what I've read.
The Seeking Alpha pumpers/bashers are seldom right and usually way too bullish or bearish. So my issue is with the quadrupling statement that the SA author claims, especially after this run-up.
I'll throw my two cents in.
Shorting any stock and especially spec stocks is extremely risky. It can go south on you very quickly. Just go ask people who shorted MNKD, ACAD, Tesla recently.
I have found that these prognosticators (seeking alpha) are seldom right especially when it comes to share price.
Congrats on a nice return.
Mo, don't believe everything you read. MNKD doesn't even have approval yet.
Nothing is guaranteed, especially quadrupling of the current market value in 7 months.
The bear argument against MNKD is that the diabetes market is already mature.
Lots of players in the space.
Even if their product is approved, not sure what percentage of diabetics would opt for an inhaler over a pill.
So basically your saying that ATRS is 100% overvalued, "at this time".
Sorry, I misinterpreted your inane stock analysis, but please keep up the good work.
I"m sure your 100% correct.
Why is $2 a fair value?
You stated in another post that the share price will drop below $1 with FDA rejection.
You need to make up your mind.
Your talking about a 85%+ decline from present share price. No way.
Just wasted your money.
They already had a meeting with the FDA about the phase III design. I hope that they're not that reckless as to start phase III without knowing phase II results were good. That would be massive mismanagement.
Either way, I will sell some shares before the June 3rd presentation and hold the rest. We shall know soon enough.